Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.
Read original at benzingaStocks · News reference
Neurimmune Sells Portion Of Its Royalty Interest In Cliramitug To Royalty Pharma For Up To $425M, Including $125M Upfront
Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royalty Pharma for up to $425 million, including $125 million upfront. The transaction provides the company access to
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 22, 2026, 10:54 AM
- Checked
- Jul 22, 2026, 10:54 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Royalty Pharma Announces $100M Agreement To Acquire Zealand Pharma's Rusfertide Economics, Including 1% Global Royalty; $50M At Closing, $50M On First Anniversary
Read original at benzingaJP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $62
JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raises the price target from $58 to $62.
Read original at benzinga8-K filing — Royalty Pharma plc (RPRX)
Filed: 2026-08-05 AccNo: 0001802768-26-000014 Size: 480 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar